Corporate Corruption News Stories

Excerpts of Key Corporate Corruption News Stories in Major Media

Below are key excerpts of revealing news articles on corporate corruption from reliable news media sources. If any link fails to function, a paywall blocks full access, or the article is no longer available, try these digital tools.

Note: This comprehensive list of news stories is usually updated once a week. Explore our full index to revealing excerpts of key major media news stories on several dozen engaging topics. And don't miss amazing excerpts from 20 of the most revealing news articles ever published.

Diesel cars produced by manufacturers like Nissan, Hyundai, Citroen and Volvo have become embroiled in the emissions scandal, after they were found to emit higher levels of pollution in tests closer to real-life driving conditions than during EU emissions tests. As reported by The Guardian, research from motoring association Adac claims that some diesel cars produced by these manufacturers emitted more than 10 times as much pollution as they did during EU emissions tests. The higher emissions were revealed when the cars were put through the WLTC test, a different test to the EU standard. The emissions scandal began when it was revealed that Volkswagen was using illegal software in their cars that could manipulate emissions and cheat US governmental tests. The software could detect when the car was being tested and cause it to emit much lower NOx levels than it would usually emit during normal driving. The CEO of Volkswagen, Martin Winterkorn, resigned after the scandal came to light, and the company is currently preparing a recall of an estimated 11 million vehicles that contain the illegal software.

Note: For more along these lines, see concise summaries of deeply revealing corporate corruption news articles from reliable major media sources.

You often hear inequality has widened because globalization and technological change have made most people less competitive, while making the best educated more competitive. There’s some truth to this. The tasks most people used to do can now be done more cheaply by lower-paid workers abroad or by computer-driven machines. But this common explanation overlooks ... the increasing concentration of political power in a corporate and financial elite that has been able to influence the rules by which the economy runs. As I argue in my new book, Saving Capitalism: For the Many, Not the Few, this transformation has ... resulted in higher corporate profits, higher returns for shareholders and higher pay for top corporate executives and Wall Street bankers – and lower pay and higher prices for most other Americans. [These changes] amount to a giant pre-distribution upward to the rich. The underlying problem ... is that the market itself has become tilted ever more in the direction of moneyed interests that have exerted disproportionate influence over it, while average workers have steadily lost bargaining power. The most important political competition over the next decades will not be between the right and left, or between Republicans and Democrats. It will be between a majority of Americans who have been losing ground, and an economic elite that refuses to recognize or respond to its growing distress.

Note: This essay was written by former Secretary of Labor Robert Reich. For more along these lines, see concise summaries of deeply revealing income inequality news articles from reliable major media sources.

According to a new book called Saving Capitalism ... rather than rescuing capitalism, the newly announced Trans-Pacific Partnership deal may simply perpetuate the problems identified by the book's author ... former U.S. labour secretary Robert Reich. From the Protection of Lawful Commerce in Arms Act, which shields the firearms industry from lawsuits by bereft family members, to laws that let companies charge high rates for slow internet, Reich offers a depressing litany of rules made by governments for the sole purpose of protecting rich corporations at the expense of the American public. "Contrary to the conventional view of an American economy bubbling with innovative small companies, the reality is quite different," Reich writes. In left-leaning circles, the conventional view is that creating equality requires redistribution of wealth from the rich to the poor. Reich says the real problem is something he calls "pre-distribution." By lobbying for laws such as those that make life-saving pharmaceuticals expensive and technological patents unbreakable, large corporations and their teams of lawyers rig the game in their favour long before the issue of redistribution arises. Drug companies are rewarded not for inventing drugs but for extending the exclusivity of existing drugs. (The TPP does exactly that.) Companies like Google, Amazon and Apple capture the value of patents and then are rewarded for "strategic litigation" to prevent anyone else from using them.

Note: For more along these lines, see concise summaries of deeply revealing news articles about government corruption and income inequality from reliable major media sources.

Risperdal is a billion-dollar antipsychotic medicine with real benefits — and a few unfortunate side effects. It can cause strokes among the elderly. And it can cause boys to grow large, pendulous breasts; one boy developed a 46DD bust. Yet Johnson & Johnson marketed Risperdal aggressively to the elderly and to boys while allegedly manipulating and hiding the data about breast development. J&J got caught, pleaded guilty to a crime and has paid more than $2 billion in penalties and settlements. But that pales next to some $30 billion in sales of Risperdal around the world. In 1994, J&J released Risperdal. The Food and Drug Administration said it ... was effective primarily for schizophrenia in adults. That’s a small market. So J&J reinvented Risperdal as a drug for a broad range of problems, targeting everyone from seniors with dementia to children with autism. The company also turned to corporate welfare: It paid doctors and others consulting fees and successfully lobbied for Texas to adopt Risperdal in place of generics. Even though Risperdal wasn’t approved for the elderly, J&J formed a sales force called ElderCare. The F.D.A. protested and noted that there were “an excess number of deaths” among the elderly who took the drug. At the same time, J&J ... began peddling the drug to pediatricians, so that by 2000, more than one-fifth of Risperdal was going to children and adolescents. In 2003, the company had a “back to school” marketing campaign for Risperdal. By 2004 Risperdal was a $3-billion-a-year drug.

Note: For more, see this NY Times article and this one. For more along these lines, see concise summaries of deeply revealing big pharma corruption news articles from reliable major media sources.

A new report provides data illustrating just how big a budgetary issue tax avoidance has become. The analysis released Tuesday comes from ... Citizens for Tax Justice and U.S. Public Interest Research Group. The groups find that almost 72 percent of Fortune 500 companies are operating subsidiaries in so-called “tax haven” countries like Bermuda and the Cayman Islands. In all, those firms are “holding more than $2.1 trillion in accumulated profits offshore for tax purposes.” The report says that among the U.S.-based firms with the biggest overseas cash holdings are major financial firms such as Citigroup and Bank of America, which were bailed out by taxpayers after the 2008 financial crisis. Also on the list are tech giants such as Microsoft - which International Business Times last year reported was keeping $92 billion offshore. Assuming a tax rate of just 6 percent on those profits - far less than the official U.S. corporate tax rate and less than Trump’s proposed “repatriation” rate - the groups estimate that the firms “would collectively owe $620 billion in additional federal taxes” if they weren’t able to shelter their cash in tax havens. For comparison, that’s more than the federal government’s entire projected budget deficit for 2015.

Note: For more along these lines, see concise summaries of deeply revealing corporate corruption news articles from reliable major media sources.

Since there have been toys, we have wanted them to speak to us. But in the past five years, breakthroughs in artificial intelligence and speech recognition have given the devices around us — smartphones, computers, cars — the ability to engage in something approaching conversation. Artificial intelligence for children [is arriving] most prominently in the pink, perky form of Mattel’s Hello Barbie. Hello Barbie is by far the most advanced to date in a new generation of A.I. toys. Every one of Barbie’s potential conversations was mapped out like the branches of a tree, with questions leading to long lists of predicted answers, which would trigger Barbie’s next response, and so on. The writers marked important questions with "flags," and this enabled Hello Barbie’s most unnerving power: She could remember the answers and use them for conversation starters days or weeks later. "She should always know that you have two moms and that your grandma died, so don’t bring that up, and that your favorite color is blue, and that you want to be a veterinarian when you grow up," [ToyTalk writer Sarah] Wulfeck said. For psychologists ... the primary concern with A.I. toys is not that they encourage kids to fantasize too wildly. Instead, researchers worry that a conversational doll might prevent children, who have long personified toys without technology, from imagining wildly enough. Hello Barbie ... is limited by programming — and public-relations concerns. Mattel, rather than kids, ultimately controls what she can say.

Note: Will this new toy have similar issues as other "smart" objects?

In 2001, a "landmark" study published in the prestigious Journal of the American Academy of Child and Adolescent Psychiatry purported to show the safety and effectiveness of using a common antidepressant to treat adolescents. The original published findings were biased and misleading. Known as Study 329, the randomised controlled trial ... was funded by SmithKline Beecham now GlaxoSmithKline (GSK) the manufacturer of paroxetine. The research has been repeatedly criticised, and there have been numerous calls for it to be retracted. To re-analyse the evidence of effectiveness and safety of paroxetine, we used documents posted online by GSK. We also had access to other publicly available documents and individual participant data. We found that paroxetine [Paxil] was no more effective than a placebo, which is the opposite of the claim in the original paper. We also found significant increases in harms with both paroxetine and imipramine, [another antidepressant]. Compared with the placebo group, the paroxetine group had more than twice as many severe adverse events, and four times as many psychiatric adverse events, including suicidal behaviours and self-harm. And the imipramine group had significantly more heart problems. Our re-analysis ... identified ten strategies used by researchers in this clinical trial to minimise apparent harms. More importantly, our findings show influential peer-reviewed research published in leading medical journals can be seriously misleading.

Note: We all know that clinical trial are skewed when they are sponsored by drug companies, but here is undeniable proof of this published in the UK's most respected medical journal. See this key study on the website of the British Medical Journal. Then don't miss that amazing documentary "Bought" available for free viewing.

Quebec-based Valeant Pharmaceutical's price hikes of drugs long off patent has raised the ire of U.S. legislators and frustrated Canadian physicians. Democrats on the House of Representatives committee on oversight and government reform sent a letter Monday to the committee's Republican chairman seeking a subpoena that would force Valeant to turn over documents tied to the U.S. price hikes of two heart drugs. In the U.S., the price of Isuprel or Isoprenaline increased 2,500 per cent and Nitropress went up 1,700 per cent in three years, as the drug changed hands. Valeant purchased the rights to both heart drugs from Marathon Pharmaceuticals in February. As huge overnight drug price hikes becomes an election issue in the U.S., some doctors in Canada struggle to get other prices rolled back. In late 2013, Valeant Canada announced that as of January 2014, the price of a one-month supply of Syprine would match the U.S. price of roughly $13,244, or about 13 times higher than the previous price. The medication makes the difference between a full and productive life or a downward course of increasing liver and neurological disease. For physicians, the price increase put them in the position of having to tell patients their disease can be managed or cured but at an out-of-pocket price of $200,000 a year for the rest of their lives.

Note: For more along these lines, see concise summaries of deeply revealing news articles about big pharma profiteering from reliable major media sources.

Until this week most of us had never heard of Daraprim, a drug that fights toxoplasmosis. But after the decision of the drug’s new owner, Turing Pharmaceuticals, to boost its cost per pill from $13.50 to a whopping $750, we’re all unlikely to forget its name or the name of Turing’s owner, 32-year-old Martin Shkreli. The outrage over the astronomical hike in a life-saving drug has opened the doors to a ... debate about the soaring costs of prescription medications in the United States. Daraprim ... has been around since the 1940s. Logic suggests that drugs that have been around for a while should decline in price. It turns out that isn’t the case. The profit-minded individual or company snaps up the patents, suddenly hikes the drug’s price and puts consumers – from insurance companies to individuals – in a position of either paying what is demanded or going without. Late this summer, Rodelis Therapeutics boosted the cost of 30 tablets of cycloserine, a tuberculosis drug, from $500 to $10,800. Early in the year, Valeant Pharmaceuticals International Inc boosted the prices of two heart drugs, Nitropress and Isuprel, by 525% and 212% on the same day that they acquired them. “Our duty is to shareholders and to maximize the value” of Valeant’s products, a company spokeswoman told the Wall Street Journal at the time.

Note: For more along these lines, see concise summaries of deeply revealing news articles about big pharma profiteering from reliable major media sources.

Sen. Elizabeth Warren, stepping up her crusade against the power of wealthy interests, accused a Brookings Institution scholar of writing a research paper to benefit his corporate patrons. Warren’s charge prompted a swift response, with Brookings seeking and receiving the resignation of the economist, Robert Litan, whose report criticized a Warren-backed consumer-protection rule targeting the financial services industry. Warren leveled her criticisms in letters sent Tuesday to Brookings leaders and the Obama administration, citing the $85,000 combined fee that Litan and a co-author received from [Capital Group, a leading mutual fund manager]. Warren called the report “highly compensated and editorially compromised work on behalf of an industry player seeking a specific conclusion.” Her complaint pointed to a relatively new form of influence peddling in the nation’s capital, with industry groups and even foreign governments paying think tanks and scholars for research papers that support lobbying goals. Brookings over the past decade has embarked on aggressive fundraising drives to pay for major expansions. Investigations last year by The Washington Post, the New York Times and others found that donors had gained the ability to influence Brookings’s events and research agenda.

Note: Read about how big money buys off institutions democracy depends on. For more along these lines, see concise summaries of deeply revealing corporate corruption news articles from reliable major media sources.

The head of a US pharmaceutical company has defended his company's decision to raise the price of a 62-year-old medication used by Aids patients by over 5,000%. Turing Pharmaceuticals acquired the rights to Daraprim in August. After Turing's acquisition, a dose of Daraprim in the US increased from $13.50 (Ł8.70) to $750. The pill costs about $1 to produce, but [CEO Martin] Mr Shkreli, a former hedge fund manager, said that does not include other costs like marketing and distribution, which have increased dramatically in recent years. "We needed to turn a profit on this drug," Mr Shkreli told Bloomberg TV. "The companies before us were actually giving it away almost." He says the practice is not out of line with the rest of the industry. "Daraprim is still underpriced relative to its peers," he told Bloomberg TV. The Infectious Diseases Society of America, the HIV Medicine Association and other health care providers wrote an open letter to Turing, urging the company to reconsider.

Note: Following public outcry, Martin Shkreli now says that Daraprim's price will not increase by 5000%, but the fact that this would even be consider shows how rampant corruption is in the industry. For more along these lines, see concise summaries of deeply revealing big pharma corruption news articles from reliable major media sources.

The National Security Agency’s ability to spy on vast quantities of Internet traffic passing through the United States has relied on its extraordinary, decades-long partnership with a single company: the telecom giant AT&T. The N.S.A.’s top-secret budget in 2013 for the AT&T partnership was more than twice that of the next-largest such program, [and] the company installed surveillance equipment in at least 17 of its Internet hubs on American soil, far more than its similarly sized competitor, Verizon. After the terrorist attacks of Sept. 11, 2001, AT&T ... began turning over emails and phone calls “within days” after the warrantless surveillance began in October 2001. In 2011, AT&T began handing over 1.1 billion domestic cellphone calling records a day to the N.S.A. after “a push to get this flow operational prior to the 10th anniversary of 9/11,” according to an internal agency newsletter. In a 2006 lawsuit, a retired AT&T technician named Mark Klein claimed that ... he had seen a secret room in a company building in San Francisco where the N.S.A. had installed equipment. Mr. Klein claimed that AT&T was providing the N.S.A. with access to Internet traffic that AT&T transmits for other telecom companies. Such cooperative arrangements, known in the industry as “peering,” mean that communications from customers of other companies could end up on AT&T’s network.

Note: The story of Klein's lawsuit was initially suppressed by the NSA and major media including the L.A. Times. For more along these lines, see concise summaries of deeply revealing news articles about questionable intelligence agency practices and the erosion of privacy.

General Motors has agreed to pay a $900m fine to avoid a criminal investigation into allegations that it deliberately hid information about a fault that led to the deaths of at least 124 people. As part of the settlement with the Department of Justice on Thursday, GM admitted that it “failed to disclose to its US regulator and the public a potentially lethal safety defect” and “further affirmatively misled consumers about the safety of GM cars afflicted by the defect”. The company paid the fine in order to avoid being criminally charged with scheming to conceal the fact that a fault with its ignition switch could lead to engines suddenly turning off and brakes being disabled. America’s largest car maker eventually recalled 2.6m cars to replace the faulty ignition switch. An investigation found that GM engineers and lawyers knew about the defect for more than a decade before the company admitted to any problem and began the recall. GM fired 15 employees following the 2014 internal investigation. Clarence Ditlow, executive director of the Center for Automotive Safety, a nonprofit advocacy group, said: “GM killed over a 100 people by knowingly putting a defective ignition switch into over 1 million vehicles. Today thanks to its lobbyists, GM officials walk off scot-free while its customers are six feet under.”

Note: For more along these lines, see concise summaries of deeply revealing corporate corruption news articles from reliable major media sources.

Corporations have poured money into universities to fund research for decades, but now, the debate over bioengineered foods has escalated into a billion-dollar food industry war. Companies like Monsanto are squaring off against major organic firms like Stonyfield Farm. Both sides have aggressively recruited academic researchers. The biotech industry has published dozens of articles, under the names of prominent academics, that in some cases were drafted by industry consultants. Monsanto and its industry partners have also passed out an undisclosed amount in special grants to scientists ... to help with “biotechnology outreach” and to travel around the country to defend genetically modified foods. The moves by Monsanto, in an alliance with the Biotechnology Industry Organization and the Grocery Manufacturers Association, are detailed in thousands of pages of emails that were at first requested by the nonprofit group U.S. Right to Know, which receives funding from the organic foods industry. The emails show how academics have shifted from researchers to actors in lobbying and corporate public relations campaigns. An inner circle of [biotech] industry consultants, lobbyists and executives ... devised strategy on how to block state efforts to mandate G.M.O. labeling. The opponents of genetically modified foods have used their own creative tactics, although their spending on lobbying and public relations amounts to a tiny fraction of that of biosciences companies.

Note: Read an article which takes it even deeper and shows what the NYT left out. For more along these lines, see concise summaries of deeply revealing news articles about the corruption of science and the controversy surrounding GMOs.

A US government-appointed agricultural body tried to crush a Silicon Valley food startup after concluding the company represented a “major threat” and “crisis” for the $5.5bn-a-year egg industry, according to documents obtained by the Guardian. In potential conflict with rules that govern how it can spend its funds, the American Egg Board (AEB) lobbied for a concerted attack on Hampton Creek, a food company that has created a low-cost plant-based egg replacement and the maker of Just Mayo, a mayonnaise alternative. The AEB attempted to have Just Mayo blocked from Whole Foods, asking Anthony Zolezzi, a partner at private equity firm Pegasus Capital Advisors ... to use his influence with Whole Foods to drop the product. (Whole Foods still sells Just Mayo.) More than one member of the AEB made joking threats of violence against Hampton Creek’s founder, Josh Tetrick. “Can we pool our money and put a hit on him?” asked Mike Sencer, executive vice-president of AEB member organization Hidden Villa Ranch. The AEB represents egg farmers across the US and its board is selected by the secretary of agriculture. The Department of Agriculture (USDA) ... suggested [additional] ways to put pressure on Hampton Creek. In January 2014, Roger Glasshoff, then the USDA’s head of shell eggs, told [Outgoing AEB head Joanne] Ivy to contact the FDA about Just Mayo directly. Last month the FDA ruled that Just Mayo could not be called mayonnaise because it does not contain eggs.

Note: Read another news article about Hampton's inspiring success. The USDA allows foods with non-organic ingredients to be labelled "USDA organic". The FDA has no problem allowing cloned animals into the food supply. When government corruption is the standard, anything is possible. But not egg-free mayo.

In the early 1980s, DuPont, which ran a sprawling chemical plant called Washington Works in nearby Parkersburg, approached [Jim Tennants'] family about buying some acreage for a landfill. DuPont assured them it would only dispose of non-toxic material. They agreed to sell. In the mid-1990s ... the family began finding dead deer. The cattle started going blind, sprouting tumors, vomiting blood. Family members were being hospitalized for breathing problems and chemical burns. Convinced that the landfill was to blame, the Tennants tried unsuccessfully to get help from environmental agencies, [and eventually sued] DuPont [with the help of attorney] Rob Bilott. In August 2000, Bilott came across a single paper that mentioned ... C8, [which] is found in thousands of household products. The judge in the Tennant case eventually forced DuPont to turn over thousands of documents on C8. And that’s when the picture finally snapped into focus. The documents revealed that DuPont had used the landfill near the Tennants’ farm as part of an increasingly elaborate cover-up. After discovering C8 in [the nearby town] Lubeck’s water supply in the early 1980s, DuPont had dredged up 14 million pounds of C8-laced sludge from the unlined pits near the town wells and dumped it into the Dry Run landfill. But the C8 levels in Lubeck’s water kept climbing. To hide this ... DuPont devised a testing method that grossly underestimated C8 levels.

Note: DuPont wove a complex web of lies over a period of decades to cover up C-8's massive harms. The link above tells this story as a comprehensive multimedia presentation. For more along these lines, see concise summaries of deeply revealing corporate corruption news articles from reliable major media sources.

Pediatrician Carla Nelson ... waited for the ambulance plane to take the infant from Waimea, on the island of Kauai, to the main children’s hospital in Honolulu. It was the fourth [severe heart malformation] she had seen in three years. There have been at least nine in five years, she says, shaking her head. That’s more than 10 times the national rate. Corn that’s been genetically modified to resist pesticides [is] a major cash crop on four of [Hawaii's] six main islands. In Kauai, chemical companies Dow, BASF, Syngenta and DuPont spray 17 times more pesticide per acre than on ordinary cornfields in the US mainland. About a fourth of the total are called Restricted Use Pesticides because of their harmfulness. Just in Kauai, 18 tons – mostly atrazine, paraquat (both banned in Europe) and chlorpyrifos – were applied in 2012. The World Health Organization this year announced that glyphosate, sold as Roundup, the most common of the non-restricted herbicides, is “probably carcinogenic in humans”. When the spraying is underway ... residents complain of stinging eyes, headaches and vomiting. At these times, many crowd the waiting rooms of the town’s main hospital, which was run until recently by Dow AgroSciences’ former chief lobbyist in Honolulu. The chemical companies that grow the corn ... refuse to disclose with any precision which chemicals they use, where and in what amounts, but they insist the pesticides are safe. Today, about 90% of industrial GMO corn grown in the US was originally developed in Hawaii.

Note: For more along these lines, see concise summaries of deeply revealing GMO news articles from reliable major media sources.

The world’s largest defense contractor has agreed to pay $4.7 million to settle charges that it illegally used government money. Top executives for Lockheed Martin — who were being paid by the federal government to run Sandia National Laboratories — ran a fierce campaign to lobby [government] officials for a seven-year extension of their contract, [and] urged them to close the bidding to competition. To clinch the contract extension, Sandia labs officials hired high-priced consultants — including Heather A. Wilson, the former New Mexico congresswoman, who allegedly was paid $226,000. Wilson was not just on Lockheed’s payroll. From 2009 through 2011, she had consulting jobs for Lockheed and three other contractors managing the Energy Department’s national lab, charging taxpayers a total of $450,000. But the contractors could not document her work, said [Energy Department Inspector General Gregory] Friedman, whose staff found that the justification for the billing did “not meet even minimum standards” for federal payments.” Wilson ... left Congress in 2009. Jay Coghlan of Nuclear Watch New Mexico, called the deal a “slap on the wrist for the world’s biggest defense contractor to pay,” [and] wrote on the NuclearWatch blog Lockheed “engaged in deep and systemic corruption, including paying Congresswoman Heather Wilson $10,000 a month starting the day after she left office for so-called consulting services that had no written work requirements.”

Note: Lockheed Martin runs a breathtakingly big part of the United States. For more along these lines, see concise summaries of deeply revealing news articles about corruption in government and in the corporate world.

Peer review is supposed to be the pride of the rigorous academic publishing process. But increasingly journals are finding out that those supposedly authoritative checks are being rigged. In the latest episode of the fake peer review phenomenon, one of the world’s largest academic publishers, Springer, has retracted 64 articles from 10 of its journals after discovering that their reviews were linked to fake e-mail addresses. The announcement comes nine months after 43 studies were retracted by BioMed Central (one of Springer’s imprints) for the same reason. Retraction Watch co-founder Ivan Oransky ... said he didn’t know of any instances of retractions for faked peer reviews before 2012. In a report for the journal Nature last fall, Oransky and his colleagues told the story of a ... researcher who wrote peer reviews for 28 of his own papers. Investigations ... have also uncovered a number of services selling names and contact information for made-up experts guaranteed to give an expedited, positive review. In a statement on its Web site in February, the Committee on Publication Ethics (COPE) detailed these agencies’ “systematic, inappropriate attempts” to manipulate the process. COPE’s chair Ginny Barbour wrote in December, “The uncovering of companies systematically manipulating publications, by the use of fake reviewers and more, offers an alarming glimpse into what can happen if reward systems are implemented with no thought or oversight.”

Note: The editor of a top medical journal recently suggested that half all of scientific literature may simply be untrue. For more along these lines, see concise summaries of deeply revealing news articles about corruption in science.

If you were freaked out by the news in June that an anesthesiologist had talked trash about her patient while he was unconscious on the table in front of her, you'd better brace yourself. There's more and it's ... much worse. In an anonymous essay published in the Annals of Internal Medicine this week, one physician describes — in graphic detail — what happened to two women when they were asleep in operating rooms. The stories are horrifying. "I bet she's enjoying this," one doctor reportedly said while prepping a woman for a vaginal hysterectomy. In another case, an obstetrician performed an obscene dance after saving the life of a woman who was bleeding out after having a baby. In a letter accompanying the essay, the editorial team agonized over whether to publish the piece. Everyone agreed that [it] was "disgusting and scandalous" and could damage the profession's reputation. But some argued that this was why they shouldn't publish it while others felt that was why they should publish it. In the end they said they decided to do so in order to "expose medicine's dark underbelly." They said the first incident "reeked of misogyny and disrespect — the second reeked of all that plus heavy overtones of sexual assault and racism." The journal's editors ... hope that medical educators and others will use the essay as a "jumping-off point for discussions that explore the reasons why physicians sometimes behave badly. If the essay squelches such behavior even once, then it was well worth publishing," they wrote.

Note: For more along these lines, see concise summaries of deeply revealing medical industry news articles from reliable major media sources.

Important Note: Explore our full index to revealing excerpts of key major media news stories on several dozen engaging topics. And don't miss amazing excerpts from 20 of the most revealing news articles ever published.